Rigel Pharmaceuticals RIGL Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $597K-0.7% | $601K-0.3% | $603K-0.7% | $607K+0.5% | $604K0.0% | ||
| $3.46M+25.8% | $2.75M-18.3% | $3.36M+2.7% | $3.28M-1.4% | $3.32M+59.3% | ||
| $2.57M— | —— | —— | —— | $0— | ||
| -$1.82M-131% | $5.84M-3.0% | $6.02M+467% | -$1.64M-2,312% | -$68K-101% | ||
| $581K— | —— | —— | $8.37M+692% | -$1.41M+26.6% | ||
| -$2.71M-181% | $3.35M— | —— | $3.34M+442% | $615K+229% | ||
| -$5.91M-419% | $1.85M— | —— | —— | -$4.12M-286% | ||
| $3.79M+12.0% | $3.39M+80.9% | $1.87M— | —— | $13.15M— | ||
| -$145K— | —— | —— | —— | $1.04M+672% | ||
| $2.73M-87.6% | $21.98M-8.5% | $24.03M-21.3% | $30.54M+3,520% | -$893K-106% | ||
| —— | $1.25M0.0% | $1.25M0.0% | $1.25M0.0% | $1.25M0.0% | ||
| $23.92M-38.5% | $38.92M-27.8% | $53.89M+38.1% | $39.03M+80.2% | $21.65M+22.3% | ||
| $15.95M+17.7% | $13.55M-34.6% | $20.73M+31.6% | $15.75M+41.9% | $11.1M+64.4% | ||
| -$7.98M+68.6% | -$25.36M+23.6% | -$33.18M-42.5% | -$23.28M-121% | -$10.55M— | ||
| $3.74M— | —— | —— | —— | $0— | ||
| $7.5M— | —— | —— | —— | $0— | ||
| $321K-89.0% | $2.93M-31.4% | $4.27M+922% | $418K-13.6% | $484K-67.0% | ||
| -$10.92M— | —— | $4.27M+922% | $418K-13.6% | $484K— | ||
| -$16.17M-103% | -$7.95M-63.2% | -$4.87M— | —— | -$10.96M-317% | ||
| $1.32M-15.6% | $1.56M-6.7% | $1.68M-0.1% | $1.68M+1.6% | $1.65M-5.4% | ||
| —— | $265.75K0.0% | $265.75K0.0% | $265.75K0.0% | $265.75K+221% | ||
| $218K-69.2% | $708K+1.9% | $695K— | —— | $575K+19.8% | ||
| -$5.91M-419% | $1.85M— | —— | —— | -$4.12M-286% | ||
| -$145K— | —— | —— | —— | $1.04M+672% | ||
| -$1.79M— | —— | —— | —— | -$2.95M-789% | ||
| $3.79M+12.0% | $3.39M+80.9% | $1.87M— | —— | $13.15M— | ||
| $135K— | —— | —— | —— | -$1.06M-766% | ||
| $170K-30.0% | $243K-48.0% | $467K+86.8% | $250K+31.6% | $190K-31.2% | ||
| $364K— | —— | $518K-66.9% | $1.57M+4.8% | $1.5M-64.8% | ||
| $23.92M-38.5% | $38.92M-27.8% | $53.89M+38.1% | $39.03M+80.2% | $21.65M+22.3% | ||
| $15.95M+17.7% | $13.55M-34.6% | $20.73M+31.6% | $15.75M+41.9% | $11.1M+64.4% | ||
| $321K-89.0% | $2.93M-31.4% | $4.27M+922% | $418K-13.6% | $484K-67.0% | ||
| $7.5M— | —— | —— | —— | $0— | ||
| -$145K— | —— | —— | —— | $1.04M+672% | ||
| $5M— | —— | —— | —— | $5M— | ||
| $0— | —— | —— | —— | $1.22M— | ||
| —— | $265.75K0.0% | $265.75K0.0% | $265.75K0.0% | $265.75K+221% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Rigel Pharmaceuticals generate?
- Rigel Pharmaceuticals (RIGL) generated $79.3M in operating cash flow over the trailing twelve months.
- Where does Rigel Pharmaceuticals's cash flow data come from?
- Every line is extracted from Rigel Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
